



OPTIGEN® LLC

for the genetic advantage

Test Report

JOCELYNE MICHE CHARTRAIN
14 RUE DES COTES
SAINT-JUST, - 27950
France

Optigen Accession #: **15-3862**
Report issued for: **EVER-BLUE-BOY DU ROYAUME DES ANGES**

OptiGen Test Certificate

Optigen Accession #: **15-3862**

Test Completed: **05/14/2015**
Report Issued: **05/14/2015**

Test Performed: **Pap_PRA1**

Result: **Normal**
Sample Type: **Swab**

Registered Name: **EVER-BLUE-BOY**

Reg#: **11362/2158**

Breed: **Epagneul Nain Continental (Papillon)**

ID#: **250269801472985**

Sex: **Male**

Date of Birth: **December 27, 2009**

Owner(s):

JOCELYNE MICHE CHARTRAIN



Susan Pearson Kelling
OptiGen Authorized Signature

www.optigen.com

Test Results: Genotype of your dog is **NORMAL**

Risk for developing Papillon PRA1: This dog will not develop the form of Progressive Retinal Atrophy caused by the Pap_PRA1 mutation.

Significance for breeding: Genetically Normal/Clear dogs can be bred to any dog and will produce no pups affected with PRA due to the Pap_PRA1 mutation.

Other PRA(s): Please note that at least one other form or PRA in addition to Papillon PRA1 is known to occur in the Papillon. No DNA test is currently available for the other form(s) of PRA in the Papillon.

For further information, please consult the OptiGen website at www.optigen.com

International DNA Based Genetic Database: To register this result with OFA, make a copy, sign below, mail WITH FEE, to OFA, 2300 E. Nifong Blvd, Columbia, MO 65201-3856 or FAX to 573-875-5073. www.ofa.org
I hereby certify that the sample submitted was of the animal described on this application. I authorize the OFA to release all information on the test results thus placing the results in the public domain and I hereby release OFA from any and all liability associated with the release of test information.

Signature of owner or authorized representative: _____

Cornell Business & Technology Park

tel: 607.257.0301

fax: 607.257.0353

767 Warren Road, Suite 300, Ithaca, NY 14850

email: genetest@optigen.com

web: www.optigen.com